Physician profile
Cheryl Carter
NPI 1174571525
$8,671.67
in general payments reported to CMS, 2019-2025
42 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,160 · 2022: $1,716 · 2023: $1,204 · 2024: $1,461 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.73 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,388.14 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,118.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $673.43 | 2021-2025 | |
| Corcept Therapeutics | $652.88 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.21 | 2021-2025 | Jardiance |
| Abbvie INC. | $408.15 | 2021-2024 | |
| Axsome Therapeutics, INC. | $356.35 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $350.25 | 2021-2024 | |
| Amgen INC. | $299.74 | 2021-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $278.47 | 2021-2025 | |
| Lilly USA, LLC | $270.57 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $237.86 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $215.17 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $172.76 | 2021-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $163.44 | 2021-2024 | Rexulti |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $152.42 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $151.62 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Abbott Laboratories | $126.31 | 2021-2025 | Freestyle Libre |
| Bausch Health US, LLC | $125.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $100.92 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $83.88 | 2025 | Voquezna |
| Lundbeck LLC | $80.14 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $72.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.23 | 2022 | |
| Radius Health, INC. | $55.34 | 2024-2025 | Tymlos |
| Mylan Specialty L.P. | $51.45 | 2021-2022 | |
| Medtronic, INC. | $50.87 | 2021-2025 | Minimed 780g |
| Idorsia Pharmaceuticals US INC | $48.73 | 2023-2024 | Quviviq |
| Insulet Corporation | $46.52 | 2024 | Omnipod |
| Glaxosmithkline, LLC. | $42.10 | 2023-2024 | Trelegy Ellipta |
| Cequr Corporation | $40.22 | 2021 | |
| Pfizer INC. | $30.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.64 | 2021-2024 | Zoryve |
| Antares Pharma, INC. | $22.41 | 2022 | |
| Biogen, INC. | $20.23 | 2023 | Skyclarys |
| Sequel Med Tech, LLC | $17.27 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $16.72 | 2022 | |
| Halozyme INC | $16.61 | 2023 | |
| Eisai INC. | $16.29 | 2021 | |
| Almatica Pharma LLC | $15.15 | 2022 | |
| Amarin Pharma, INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.